Who: Sanofi/Formation Bio
What: The French drugmaker has licensed gusacitinib, an oral dual JAK/SYK inhibitor.
Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.
